Compare Global X SuperDividend ETF (SDIV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Global X SuperDividend ETF trades at $23.65 (market cap $1.18B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 4.1× Global X SuperDividend ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 49 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SDIV | TVTX | |
|---|---|---|
Market Cap | $1.18B | $4.88B |
Volume | 591,359 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $67.52 |
52-Week Low | $23.16 | $26.79 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.88, down 0.21% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, with a 66% price decline since inception noted by Seeking Alpha on September 11, 2026. Recent institutional buying includes Ameritas Advisory increasing its position by 92.6% in Q2 2026 per SEC filings.
High dividend yield attracts income investors but comes with significant capital depreciation risks. Media coverage highlights sustainability concerns, while technical indicators suggest near-term consolidation. The outlook remains cautious due to persistent underperformance versus benchmarks and high volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
